
|Videos|December 8, 2017
Dr. Zhang Discusses the KEYNOTE-564 Trial in RCC
Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the KEYNOTE-564 trial in renal cell carcinoma.
Advertisement
Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the KEYNOTE-564 trial in renal cell carcinoma (RCC).
KEYNOTE-564 is an ongoing trial that is randomizing patients to pembrolizumab (Keytruda) or placebo, with a primary endpoint of disease-free survival.
This trial is enrolling high-risk patients with RCC, says Zhang, but it will also enroll patients with metastatic disease and have had metastasectomies—which is a unique feature of KEYNOTE-564.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5




































